GSK plc GSK announced that it has signed an agreement with Massachusetts-based biopharmaceutical company Boston ...

Something seems to be going awry with GlaxoSmithKline's game plan for its respiratory franchise, with new products positioned to replace ageing blockbuster Advair/Seretide not performing in the field.

The pharma company said it expects more approvals through the year following positive results from a Phase 3 trial.

This was due to continued investments by GSK for launching new products and supporting the global market expansion of its existing marketed drugs. Core research and development expenses rose 2% to ...

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has authorised GSK’s Blenrep for treating multiple myeloma (MM).

GSK is focusing on expanding newer products, particularly in infectious diseases, to offset declining sales from top drugs and vaccines as demand slows and competition increases. GSK is also ...

GSK on Wednesday said it was "well positioned" to absorb potential U.S. pharmaceutical tariffs, citing AI-driven cost cuts ...